These are top 10 stocks traded on the Robinhood UK platform in July
In a recent SEC filing, Vericel Corp (NASDAQ:VCEL) Director Kevin McLaughlin disclosed the sale of 7,000 shares of the company's common stock on February 12, 2025. The stock currently trades at $57.09, near its 52-week high of $63, after gaining over 25% in the past six months. According to InvestingPro analysis, the company maintains a GOOD financial health score despite trading at premium valuations. The shares were sold at prices ranging from $55.43 to $55.47, amounting to a total transaction value of $388,250. The sales were executed under an automatic trading plan established in March 2024.
Additionally, McLaughlin exercised options to acquire 7,000 shares at prices between $2.76 and $3.74, with the total value of these transactions reaching $25,200. Following these transactions, McLaughlin holds 14,000 shares of Vericel common stock.
In other recent news, Vericel Corporation has been in the spotlight due to its financial performance and growth trajectory. Canaccord Genuity has raised its price target for Vericel from $64 to $67, maintaining a Buy rating. This follows the company's recent preannouncement of Q4 2024 results and its 2025 guidance. The projected revenue for 2026 is estimated to reach $352.6 million, a promising sign of the company's financial prospects.
H.C. Wainwright also reaffirmed a Buy rating for Vericel, setting a price target of $60.00. This comes after Vericel reported preliminary Q4 2024 revenues, falling short of analyst expectations, but showing substantial growth in its MACI product sales. The company also revealed plans for the submission of an IND application for MACI Ankle in the first half of 2025.
Canaccord Genuity has reiterated its Buy rating on Vericel, despite Q4 revenue falling short of estimates. The company's MACI product, however, surpassed revenue expectations. Looking ahead, Vericel projects a total revenue growth of 20-23% for 2025.
Lastly, Truist Securities has upgraded its price target on Vericel to $67.00, indicating confidence in the company's growth trajectory. These recent developments highlight the financial performance and growth prospects of Vericel Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.